+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Brain Tumor Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4774927
  • Report
  • May 2019
  • Region: Global
  • 114 pages
  • Mordor Intelligence
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • MORE
Market Overview

A brain tumor occurs when abnormal cells from within the brain. There are two major types of tumors, malignant or cancerous tumors and benign tumors. Increasing incidence of the brain tumor is one of the major factors which is driving the growth of the market globally. As per the Central Brain Tumor Registry of the United States report 2016, an estimated 79,270 new cases of primary malignant, nonmalignant are anticipated to be diagnosed in the US in 2017 (26,070 primary malignant and 53,200 nonmalignant). The rising prevalence of brain cancer cases across the globe is expected to drive the demand of the brain tumor therapeutics market over the forecast period. The high cost of cancer therapy is one of the major factors restraining the growth of the market studied. The treatment for brain tumor differs depending on several factors, such as age, general health, and the size, location, and type of tumor. Furthermore, there are some adverse effects of the treatments that are restraining the growth of the market studied, over the forecast period.

Scope of the Report

Brain tumor arises from abnormal growth of cancerous cells in the brain. A brain tumor is one of the leading causes of death, globally. Meningioma is the most common kind of brain tumor and the hardest to treat, while, treatments for glioma usually have better outcomes.

Key Market Trends

Immunotherapy Segment is Expected to Register Robust Growth

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Vaccines are a promising new form of immunotherapy that stimulates the immune system to fight cancer. The use of immunotherapy in glioblastoma multiforme which is the most common primary malignant brain tumor in adults has been found to be effective. In 2018, a European trial succeeded in proving the feasibility and efficacy of treating brain cancer with personalized immunotherapy tailored for each patient. This phase I/II trial that runs across six European centers, tested a combination of two personalized vaccines in patients with glioblastoma. These clinical trials are expected to drive the market studied.

The United States is Expected to Retain Largest Market Share During the Period of Forecast.

The US dominates the brain tumor treatment market in North America. The US is anticipated to lead the market owing to the developed healthcare industry coupled with rising awareness regarding advanced technologies amongst the population in this region. In the United States, the incidence of all primary malignant and non-malignant brain and other CNS tumors is 22.36 cases per 100,000, for a total count of 368,117 tumor incidences. Meningioma is the most common form of brain tumor, followed by Gliomas. Eflornithine is designated as an orphan drug in the United States and received Breakthrough Therapy Designation in the country for the treatment of anaplastic Glioma

Competitive Landscape

The market for brain tumor therapeutics is highly concentrated with a few global players controlling a significant share of the market. Key players in the market include Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Novartis AG, and Pfizer Inc. among others.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5


  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Brain Tumor
4.2.2 Strong R&D Initiatives from Key Players
4.2.3 Increasing Government Initiatives for Cancer Awareness
4.3 Market Restraints
4.3.1 High Cost of Cancer Therapies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Brain Cancer
5.1.1 Glioblastoma
5.1.2 Meningioma
5.1.3 Pituitary Tumors
5.1.4 Other Types of Brain Cancer
5.2 By Therapy
5.2.1 Tissue Engineering
5.2.2 Immunotherapy
5.2.3 Gene Therapy
5.2.4 Other Therapies
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 Bristol-Myers Squibb Co
6.1.5 Eisai Inc.
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 GlaxoSmithKline PLC
6.1.8 Johnson & Johnson
6.1.9 Merck & Co. Inc.
6.1.10 Novartis AG
6.1.11 Pfizer Inc.

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 5